← Back to Analyst Consensus 
CATX Buy
Perspective Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 7, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Sep 18, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Sep 15, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Aug 19, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Aug 14, 2026 | B of A Securities | maintain | Neutral → Neutral | — | 53% |
| Aug 11, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| May 5, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| May 5, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Apr 20, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Mar 23, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 18, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 54% |
| Mar 18, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Mar 18, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Mar 17, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Mar 17, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Feb 19, 2026 | Piper Sandler | initiate | — → Overweight | $16 | 54% |
| Jan 30, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Jan 30, 2026 | Wedbush | reiterate | Outperform → Outperform | $11 | 58% |
| Jan 13, 2026 | BTIG | reiterate | Buy → Buy | $14 | 52% |
| Nov 21, 2025 | UBS | maintain | Buy → Buy | $7 | 54% |
| Nov 18, 2025 | B. Riley Securities | maintain | Buy → Buy | $11 | 54% |
| Oct 13, 2025 | BTIG | reiterate | Buy → Buy | $14 | 52% |
| Oct 10, 2025 | BTIG | initiate | — → Buy | $14 | 52% |
| Oct 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jun 23, 2025 | B. Riley Securities | maintain | Buy → Buy | $12 | 54% |
| Jun 23, 2025 | Wedbush | reiterate | Outperform → Outperform | $11 | 58% |
| Jun 3, 2025 | RBC Capital | maintain | Outperform → Outperform | $16 | 55% |
| May 14, 2025 | Truist Securities | maintain | Buy → Buy | $8 | 54% |
| Apr 7, 2025 | Truist Securities | maintain | Buy → Buy | $10 | 54% |
| Mar 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 27, 2025 | RBC Capital | maintain | Outperform → Outperform | $15 | 55% |
| Mar 27, 2025 | Wedbush | reiterate | Outperform → Outperform | $11 | 58% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 13, 2025 | HC Wainwright & Co. | initiate | — → Buy | $10 | 44% |
| Mar 7, 2025 | Scotiabank | initiate | — → Sector Outperform | $15 | 55% |
| Jan 14, 2025 | RBC Capital | reiterate | Outperform → Outperform | $16 | 55% |
| Nov 25, 2024 | RBC Capital | maintain | Outperform → Outperform | $16 | 55% |
| Nov 25, 2024 | B of A Securities | downgrade | Buy → Neutral | $6 | 53% |
| Nov 22, 2024 | Oppenheimer | maintain | Outperform → Outperform | $16 | 52% |
| Oct 24, 2024 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Oct 24, 2024 | UBS | initiate | — → Buy | $20 | 54% |
| Oct 11, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $22 | 52% |
| Oct 1, 2024 | Wedbush | initiate | — → Outperform | $25 | 58% |
| Sep 25, 2024 | Truist Securities | initiate | — → Buy | $21 | 54% |
| Sep 10, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 6, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 3, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Aug 16, 2024 | RBC Capital | maintain | Outperform → Outperform | $27 | 55% |
Price Target Trend
Jun 11, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days